Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
77results about How to "Ability to inhibit metastasis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-tumor nano medicine based on cross-linking biodegradable polymer vesica and preparation method of anti-tumor nano medicine
ActiveCN105997880AGood biocompatibilityImproved controlled releaseOrganic active ingredientsPeptide/protein ingredientsCross-linkCancer cell
The invention discloses an anti-tumor nano medicine based on cross-linking biodegradable polymer vesicae and a preparation method of the anti-tumor nano medicine. The anti-tumor nano medicine is prepared by loading a medicine on reversible cross-linking biodegradable polymer vesicae of asymmetric membrane structures; the medicine is a protein medicine, a polypeptide drug or a small molecule medicine; the reversible cross-linking biodegradable polymer vesicae of the asymmetric membrane structures are prepared from a polymer in a manner of self-assembling and cross-linking in sequence; the molecular chain of the polymer comprises a hydrophilic chain segment, a hydrophobic chain segment and PEI molecules which are connected in sequence; the hydrophobic chain segment comprises a polycarbonate chain segment and / or polyester chain segment; the medicine can be compounded and loaded under the electrostatic interaction of PEI; a membrane is reversible cross-linking biodegradable polyester / polycarbonate which is good in compatibility; dithiolane of a side chain is similar to a human body natural antioxidant lipoic acid; a shell takes PEG as a background and can target to cancer cells; the anti-tumor nano medicine has the potential to be a nano medicine system with advantages of simplicity, stability, multifunction and the like.
Owner:SUZHOU UNIV
Whitening essence and preparation method thereof
PendingCN111067818AInhibit transferPhotoprotectiveCosmetic preparationsToilet preparationsAcropustulosisButanediol
The invention provides whitening essence and a preparation method thereof. The whitening essence consists of the following components of glycerine, 1,3-butanediol, sodium hyaluronate, EDTA-2Na, polyglycerol-10, sodium polyacrylate, xanthan gum, hydroxyacetophenone, dipotassium glycyrrhizinate, hydrolyzed sclerotium gum, gluconic acid sodium salt, glycereth-26, caprylhydroxamic acid, glycerol caprylate, 3-o-ethyl ascorbic acid, tranexamic acid, ceramide, phenethyl resorcinol, diglucosyl gallic acid and water. The whitening essence disclosed by the invention can refrain conversion of tyrosine tomelanin before the tyrosine is in preparation of conversion to the melanin, so that the activity of the tyrosinase is also high, generation of more melanin cannot be caused, and transfer of skin melanin can also be restrained. Besides, the whitening essence has powerful antioxidant ability, has light protection effects on skin, can control dermatitis, and is a whitening product most comprehensivein action mechanism at present, so that whitening effects can be achieved.
Owner:广州市柏姿生物科技有限公司
Reversibly crosslinked biodegradable polymersome with asymmetric membrane structure as well as preparation method and application thereof to nucleic acid medicines
ActiveCN106177975AImprove loading performanceAvoid stabilityOrganic active ingredientsGenetic material ingredientsCancer cellSide effect
The invention discloses a reversibly crosslinked biodegradable polymersome with an asymmetric membrane structure as well as a preparation method and application thereof to nucleic acid medicines. The polymersome and the preparation method have the advantages that a triblock polymer PEG-P(TMC-DTC)-PEI or PEG-P(DLLA-DTC)-PEI is synthesized and is self-assembled and self-crosslinked to obtain the polymersome with the asymmetric membrane structure or the triblock polymer is linked with a targeting molecule and is self-assembled to obtain targeting RCCPs; the inner shell of the polymersome is PEI and is used for compounding and loading nucleic acid through electrostatic interaction; a membrane is reversibly crosslinked biodegradable polyester / polycarbonate with good biocompatibility; dithiolane of a side chain is similar to a human body natural antioxidant lipoic acid; the outer shell of the polymersome takes PEG as the background and can target cancer cells; by studying that the carrier is compounded with functional siRNA and studying the gene silencing effects in vitro and vivo, in vivo blood circulation and bio-distribution, the condition of treating lung cancer in situ bearing mice and toxic and side effects of the polymersome, the polymersome is expected to become a nanosystem platform integrating the advantages of simplicity, stability, multifunction, and the like and is used for carrying out efficient and active targeting delivery on siRNA to tumors in situ.
Owner:SUZHOU UNIV
Application of long-chain non-coding RNA gene LOC553103 to preparation of nasopharyngeal darcinoma cell inhibitors
ActiveCN105233304AGrowth inhibitionPrevent proliferationGenetic material ingredientsAntineoplastic agentsNasopharyngeal carcinomaNon-coding RNA
The invention discloses application of a long-chain non-coding RNA (Ribose Nucleic Acid) gene LOC553103 to the preparation of nasopharyngeal darcinoma cell inhibitors. The RNA interference sequence of the LOC553103 is used for preparing a preparation for inhibiting the growth and the proliferation of nasopharyngeal darcinoma cells and preventing the tumor cell invasion migration, and is further used for preparing a preparation for inhibiting the framework assembly and reconstruction of the nasopharyngeal darcinoma cells. A powerful molecular biology tool is provided for the auxiliary treatment of the nasopharyngeal darcinoma, and profound clinical significance and important popularization and application prospects are realized.
Owner:CENT SOUTH UNIV
Application of siRNA of long non-coding RNA LINC00673 and inhibition preparation
ActiveCN106492228APrevent invasionAbility to inhibit metastasisOrganic active ingredientsGenetic material ingredientsLong non-coding RNACancer research
The invention discloses application of siRNA of long non-coding RNA LINC00673 and an inhibition preparation. The sequence of the siRNA of a targeted LINC00673 is designed, synthesized, and transfected into oral cancer cell strains. It is proved that the expression of the targeted interference LINC00673 can obviously inhibit the invasion and transfer abilities of the oral cancer cells. The inhibition preparation provides a new and potential pathway for treating an oral cancer.
Owner:CENT SOUTH UNIV
Application of etomoxir to treatment of colorectal cancer
ActiveCN107744518APromotes anoikisAbility to inhibit metastasisOrganic active ingredientsAntineoplastic agentsDrugCancer research
The invention discloses application of etomoxir to treatment of colorectal cancer and particularly relates to application of etomoxir to preparation of medicines for preventing and treating colorectalcancer, especially medicines for inhibiting colorectal cancer metastasis. The research shows that etomoxir is capable of obviously inhibiting colony formation under anoikis of colorectal cancer cells, accelerating anoikis of colorectal cancer cells and inhibiting metastasis capability of the colorectal cancer cells in the body, has an obvious effect of treating the colorectal cancer and especially has an obvious effect of inhibiting colorectal cancer metastasis, so that etomoxir can be used for treating colorectal cancer metastasi. The invention provides novel application of etomoxir, expandsthe clinical application fields of etomoxir and further provides a novel manner for treating colorectal cancer metastas; etomoxir has good popularization and application prospects.
Owner:SUN YAT SEN UNIV CANCER CENT
Polyphenol extract of trembling poplar as well as extraction method and application thereof
ActiveCN102335233AInhibitionSimple preparation processAntineoplastic agentsPlant ingredientsSocial benefitsCancer cell
The invention discloses a polyphenol extract of trembling poplar as well as an extraction method and application thereof. The extraction method of the polyphenol extract of trembling poplar comprises the following steps: baking a trembling poplar plant material at 35 DEG C, and crushing; extracting with 95% ethanol, distilling to remove a solvent to obtain residues; dissolving the residues with chloroform, filtering to obtain filtrate and a primary residue, and distilling the filtrate in reduced pressure to obtain the polyphenol extract; and dissolving the primary residue by use of methanol, and distilling the solvent at reduced pressure to obtain the polyphenol extract. The polyphenol extract of the trembling poplar is convenient to extract, has high content, can be applied to industriallarge-scale production, has remarkable effects in removing oxygen radical of animals, inhibiting generation, proliferation and transfer of tumor cells of animals, is practical in treating cancer cells, and can generate good economical and social benefits.
Owner:NANJING FORESTRY UNIV
Application of long-chain non-coding RNA gene LOC553103 in preparation of gastric cancer cell inhibitor
ActiveCN105267987AGrowth inhibitionPrevent proliferationGenetic material ingredientsAntineoplastic agentsNon-coding RNAGastric carcinoma
The invention discloses application of a long-chain non-coding RNA gene LOC553103 in preparation of a gastric cancer cell inhibitor. An RNA interference sequence of the LOC553103 is used for preparing a preparation for inhibiting growth and proliferation of gastric cancer cells and preventing invasion and transfer of the cancer cells, and further used for preparing a preparation for inhibiting assembly and reconstruction of a gastric cancer cell skeleton. A powerful molecular biology tool is provided for assisted treatment of gastric cancer, and the application has far-reaching clinical significance and important popularization and application prospect.
Owner:CENT SOUTH UNIV
Preparation method and application of highly nucleus-targeted anti-tumor nanomedicine
PendingCN110575546AIncrease lethalitySolve the bottleneck problem of easy transferOrganic active ingredientsPharmaceutical non-active ingredientsTumor targetMitomycin C
The invention belongs to the field of nanomedicine and biomedicine, and discloses a preparation method and application of highly nucleus-targeted anti-tumor nanomedicine. According to the preparationmethod and the application of the highly nucleus-targeted anti-tumor nanomedicine, a polypeptide with nucleus targeting ability and graphite powder are subjected to blending and ball milling, and polypeptide functionalized graphene (TG) with high tumor targeting ability and nucleus targeting ability is prepared under normal temperature and pressure. Furthermore, carboxyl group is introduced into the TG by using an acetic acid plasma technology, and the anti-tumor drug mitomycin C (MMC) is loaded on the TG. The prepared anti-tumor nanomedicine MMC-TG has good tumor cell nucleus targeting ability and can highly selectively target tumor cells. The tumor killing rate is 95% or above, but at the same time, the anti-tumor nanomedicine MMC-TG has little damage to normal cells. Experimental results confirm that the developed nanomedicine first plays a role in the nucleus, and has efficient tumor cell nucleus targeting ability, tumor killing ability and tumor metastasis inhibiting ability.
Owner:WENZHOU MEDICAL UNIV
Interfering RNA and lentivirus targeted to OLFM4 gene, and application thereof
InactiveCN103981186AInhibit transferGood curative effectMicrobiological testing/measurementViral/bacteriophage medical ingredientsLymphatic SpreadMalignant progression
The invention provides interfering RNA and a lentivirus vector targeted to the OLFM4 gene and application of the interfering RNA and the lentivirus vector in preparation of drugs used for preventing and treating metastasis of stomach cancer tumors to the abdominal cavity or / and the liver. According to the invention, since the interfering RNA can inhibit in vitro migration and invasion ability of gastric cancer cells and liver metastasis capability of gastric cancer cells, decreased expression of OLFM4 is a potential effective mode for treatment of malignant progression of late gastric cancer. It is further determined that an NF-kB signal is an upstream regulation transcription factor of expression of OLFM4 and the interfering RNA has NF-kB signal feeding back and regulating functions.
Owner:CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV
Platinum drugphotosensitizer-loaded protein nanoparticles and preparation method and application thereof
ActiveCN111840549ALarge particle sizeGood chemical stabilityEnergy modified materialsInorganic active ingredientsAnticarcinogenic EffectTumor target
The invention relates to platinum drugphotosensitizer-loaded protein nanoparticles and a preparation method and application thereof. The platinum drugphotosensitizer-loaded protein nanoparticles comprise platinum drugphotosensitizer complexes and proteins wrapping the platinum drugphotosensitizer complexes. Chemical therapy and photodynamic therapy are combined through an albumin nano-drug delivery system so that a synergistic anti-cancer effect is achieved, and the toxicity-reducing and efficacy-improving treatment effect is achieved. The nanoparticles prepared by the method are small in particle size, uniform in dispersion and round in shape; good chemical stability and illumination stability are realized; under the irradiation of near-infrared light, the nanoparticles have relatively high active oxygen generation capability; in addition, in cell experiments and animal experiments, it is verified that the nanoparticle has strong cytotoxicity and good in-vivo tumor targeting to tumorcells, plays a synergistic effect, reduces toxic and side effects, realizes combined treatment of tumors by chemotherapy and photodynamic therapy, and inhibits tumor metastasis.
Owner:SUZHOU UNIV
In-vitro culture device for highly simulating cancer cell migration
PendingCN109082379AAbility to inhibit metastasisSimple structureTissue/virus culture apparatusCancer cellCell layer
The invention relates to an in-vitro culture device for highly simulating cancer cell migration. The in-vitro culture device comprises a first culture container body, a second culture container body and an osmosis supporting film and is characterized in that the second culture container body is clamped to the first culture container body through an annular retainer block arranged at the top of thesecond culture container body, part of the second culture container body extends into the first culture container body, and the osmosis supporting film is arranged at the bottom end of the second culture container body. The in-vitro culture device has the advantages that the in-vitro culture device is simple in structure and high in practicality, tumor cell nutrition supply, interstitial cells, blood vessels and vascular endothelial cells are considered, the device is close to the growth and transfer environment of in-vivo tumor, tumor cells are transferred into the first culture container body through the vascular endothelial cell so as to simulate the tumor cells entering blood vessels through capillary wall cell layers, and cell migration ability is judged by calculating the number ofthe tumor cells in the first culture container body after culture is performed for a certain period of time.
Owner:WUYI UNIV +1
Application of reagent for inhibiting SGCE gene
ActiveCN111481672AInhibition of enrichmentAbility to inhibit metastasisOrganic active ingredientsInorganic active ingredientsTumor chemotherapyOncology
The invention belongs to the technical field of biology, and relates to application of a reagent for inhibiting an SGCE gene and a tumor chemotherapy drug to preparation of a drug for treating tumor chemotherapy and application of a reagent for inhibiting the SGCE gene to preparation of a drug for treating EGFR high-expression tumor. It is found that enrichment of tumor stem cells caused by chemotherapeutic drugs can be weakened after the SGCE gene is inhibited; after the SGCE is inhibited, the combination of the Cbl and the EGFR is enhanced; egfr degradation, finally, the sensitivity of the EGFR inhibitor-resistant cell strain to the EGFR inhibitor is remarkably enhanced, and it is prompted that the drug resistance of tumor cells to the EGFR inhibitor can be overcome when the inhibitor for synthesizing the SGCE and the EGFR inhibitor are jointly applied to drugs for treating EGFR high-expression tumors. Therefore, proliferation and metastatic growth of various EGFR high-expression tumors such as triple-negative breast cancer, non-small cell lung cancer, colorectal cancer and the like can be effectively inhibited by jointly inhibiting EGFR while inhibiting SGCE, and recurrence of cancer is effectively prevented. The reagent has important guiding significance in clinical application and has a wide prospect.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Application of EB virus encoded microRNA BART6-3p in preparation of nasopharyngeal carcinoma cell inhibitor
ActiveCN105288656AGrowth inhibitionPrevent proliferationOrganic active ingredientsGenetic material ingredientsMicroRNANasopharyngeal carcinoma
The invention discloses application of EB virus encoded microRNA BART6-3p in preparation of a nasopharyngeal carcinoma cell inhibitor. The microRNA BART6-3p is used for preparing a preparation for inhibiting growth and reproduction of nasopharyngeal carcinoma cells and preventing tumor cell invasion and metastasis. The microRNA BART6-3p has a sequence of CGGGGAUCGGACUAGCCUUAGA. The microRNA BART6-3p is further used for preparing a preparation for assembling and reconstructing a nasopharyngeal carcinoma cell inhibition framework. The microRNA BART6-3p provides a powerful molecular biological tool to assistant treatment of nasopharyngeal carcinoma, and has far-reaching clinical magnificence and important popularization application prospect.
Owner:CENT SOUTH UNIV
Heparin starch microsphere vascular embolizing agent with anti-tumor effect and preparation method thereof
InactiveCN109010902AGrowth inhibitionAbility to inhibit metastasisSurgical adhesivesMicrocapsulesChemical industrySide effect
The invention discloses a heparin starch microsphere vascular embolizing agent with anti-tumor effect and a preparation method thereof, which belong to the field of pharmaceutical and chemical industry, and concretely relates to the heparin starch microsphere vascular embolizing agent and the preparation method thereof. The technical problem to be solved by the present invention is to provide a heparin starch microsphere vascular embolization agent and the preparation method thereof. The method prepares heparin starch microspheres with controlled size and uniform particle size by introducing heparin with good biocompatibility and capable of inhibiting tumor growth and metastasis. The heparin starch microspheres not only have an embolization effect, but also inhibits tumor growth and metastasis, and achieves the purpose of treating cancer. The method has the advantages of simple operation, good repeatability and low temperature requirement, can prepare the heparin starch microspheres with good biocompatibility, degradability and no toxic side effects by controlling reaction conditions, can be widely used in tumor vascular embolization and treatment, and establishes a foundation forits application in the medical field.
Owner:NANJING UNIV
Preparation method of micro RNA nano microsphere and application of micro RNA nano microsphere in anti-tumor aspects
InactiveCN104436217ASave solutionSignificant carcinogenic effectPowder deliveryGenetic material ingredientsNeuroglial TumorMicrosphere
The invention relates to a preparation method of a micro RNA nano microsphere and an application of the micro RNA nano microsphere in anti-tumor aspects. The nano microsphere comprises a nano-carrier and an antisense strand miR-125b-AS of micro RNA miR-125b which is wrapped or adsorbed by the carrier and is synthesized in vitro. According to the preparation method, miR-125b-AS is prepared into the nano microsphere, the stability of the nano microsphere can be significantly increased, and the nano microsphere cannot be degraded after being stored for a week at 25 DEG C; and detected by an MTT process, the nano microsphere can be transfected into a human neuroglioma cell U87 cell without using a transfection reagent, and the proliferation of tumor cells can be significantly inhibited. Invasion and migration experiments show that the transfer ability of the tumor cells can be significantly inhibited by the nano microsphere; influences of the nano microsphere to tumor cell cycles and cell apoptosis can be detected by using flow cytometry and a TUNEL process; and meanwhile, RT-PCR and Western-blot detection results show that changes of corresponding target genes and protein expression can be caused by the nano microsphere.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Application of human SHCBP1 gene and related product
ActiveCN110791566APrevent proliferationInhibit apoptosisOrganic active ingredientsMicrobiological testing/measurementCancer cellThyroid gland cancer
The invention belongs to the field of biological medicine research, and particularly relates to application of a human SHCBP1 gene used as a target in preparing a thyroid cancer treatment medicine orpreparing a thyroid cancer diagnosis medicine. Through the broad and deep research, the invention discovers that after the expression of the human SHCBP1 gene is down-regulated by adopting an RNAi method, the multiplication of thyroid cancer cells can be effectively inhibited, the cell apoptosis is promoted, and the growth process of thyroid cancer can be effectively controlled. The siRNA or a nucleic acid building body and a slow virus containing the siRNA can specifically inhibit a multiplication capacity of the thyroid cancer cells, inhibit a tumor formation capacity of the thyroid cancer cells in a human body, promote the thyroid cancer cell apoptosis, inhibit the cloning of the thyroid cancer cells, inhibit a thyroid cancer cell metastasis capacity, inhibit a thyroid cancer cell transfer capacity and change the period distribution of the thyroid cancer cells so as to treat the thyroid cancer, so that a new direction is opened for thyroid cancer treatment.
Owner:XUZHOU CENT HOSPITAL
Application of rabeprazole sodium in preparation of medicines for inhibiting tumor cell metastasis and spread
InactiveCN104546845AAbility to inhibit metastasisReduce the number of deathsOrganic active ingredientsAntineoplastic agentsCytotoxic drugNormal cell
The invention discloses an application of rabeprazole sodium in preparation of medicines for inhibiting tumor cell metastasis and spread. The metastasis capability of tumor cells is inhibited by utilizing the medicines prepared from the rabeprazole sodium, the rabeprazole sodium refers to a low-toxicity medicine, a great blocking effect can be achieved in the tumor spreading process, meanwhile, treatment is performed by adopting other related tumor drugs, and the death amount of normal cells can be greatly reduced; and moreover, most of the existing tumor drugs are cytotoxic drugs, and lots of normal cells are killed when the tumor cells are killed.
Owner:南京格耀生物科技有限公司
Derivative of vascular endothelial growth factor receptor antagonistic peptide F56 and application thereof
ActiveCN108623694AAnti-angiogenicHas antitumor activityPeptide/protein ingredientsAntibody mimetics/scaffoldsVascular endotheliumTumor therapy
The invention provides a derivative of a vascular endothelial growth factor receptor antagonistic peptide F56 and application thereof. The derivative of the vascular endothelial growth factor receptorantagonistic peptide F56 provided by the invention is a peptide derivative constructed by connecting a MIPA-AEEA-group on the basis of the structure of the vascular endothelial growth factor receptorantagonistic peptide F56. In addition to maintaining the antagonistic effect of the F56 on the binding of a vascular endothelial growth factor (VEGF) to a receptor 1 (VEGFR1) thereof and having anti-angiogenesis and anti-tumor activities, the peptide derivative has remarkably longer action time than a polypeptide F56, and can be used in anti-angiogenesis and anti-tumor therapy.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL
Application of 4-methyl-5,6-dihydropyran-2ketone in preparing anti-hepatic fibrosis and anti-hepatoma drugs
ActiveCN110339188AAbility to inhibit metastasisSimple structureOrganic active ingredientsDigestive systemDrugLiver cancer
The invention provides application of 4-methyl-5,6-dihydropyran-2ketone in preparing anti-hepatic fibrosis and anti-hepatoma drugs, and belongs to the technical field of anti-hepatic fibrosis and anti-hepatoma drugs. It is found that the 4-methyl-5,6-dihydropyran-2ketone has good anti-hepatic fibrosis activity and activity for inhibiting the hepatoma carcinoma cell migration, and can be used for preparing the anti-hepatic fibrosis and anti-hepatoma drugs. Embodiment results show that the 4-methyl-5,6-dihydropyran-2ketone can inhibit the activity of type I collagen alpha 1 promoter, reduce theexpression of hepatic fibrosis markers such as COL1A1 and ACTA3 in hepatic stellate cells LX-2, improve the liver tissue pathological structure and hepatic fibrosis degree in BDL mice, and inhibit themigration of hepatoma carcinoma cells HepG2.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI
Application of flunarizine hydrochloride in preparation of medicines for inhibiting tumor cell metastases and spread
InactiveCN104644636ALarge blocking effectReduce the number of deathsOrganic active ingredientsAntineoplastic agentsToxicityFlunarizine Hydrochloride
The invention relates to an application of flunarizine hydrochloride in preparation of medicines for inhibiting tumor cell metastases and spread. The metastases ability of tumor cells are inhibited by medicines prepared from flunarizine hydrochloride; flunarizine hydrochloride is a low-toxicity medicine, and can play a relatively great blocking role in a tumor spreading process; meanwhile, other related tumor medicines are used in treatment, so that the mortality of normal cells can be greatly reduced; the existing tumor medicines mainly are cytotoxic medicines; and a plurality of normal cells are killed when the tumor cells are killed.
Owner:NANJING WENZHI BIOTECH
IgE antibodies for the inhibition of tumor metastasis
ActiveCN105431205AInhibition of the ability to mediate tumor metastasisAbility to inhibit metastasisAntibody ingredientsImmunoglobulinsLymphatic SpreadCancer cell
The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent the appearance of tumor metastases derived from a primary solid tumor, treating established metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
Owner:斯坦福大学董事会
Verification of ACAP4 activity inhibiting protein and functions of ACAP4 activity inhibiting protein in cell migration
InactiveCN104402986AInhibit hydrolytic activityInhibitory activityOrganic active ingredientsPeptide/protein ingredientsProtein proteinDrug
The invention discloses verification of an ACAP4 activity inhibiting protein and functions of the ACAP4 activity inhibiting protein in cell migration. The invention aims to provide an ACAP4 activity inhibiting protein and a coding gene thereof, and application of the ACAP4 activity inhibiting protein in preparing drugs for inhibiting tumor metastasis. The protein is one of the following amino acid sequences: 1) SEQ ID NO:1 in the sequence table; and 2) protein with function of regulating ACAP4 and ARF6 activity subjected to substitution, deletion or addition of one to ten amino acid residues on the amino acid residue sequence disclosed as SEQ ID NO:1 in the sequence table. The protein is an ACAP4-activity-inhibiting protein, and can display the signal passage function and regulate the migration function of tumor cells by regulating the combining capacity with ACAP4 and the activity of the substrate ARF6. Therefore, the protein can be used as a drug target to perform screening on small-molecule compounds, thereby detecting possible drugs for inhibiting tumor cell metastasis. The protein and coding gene thereof can perform important functions in the fields of medicine and pharmacy, and have wide prospects.
Owner:UNIV OF SCI & TECH OF CHINA
Reversible cross-linked biodegradable polymer vesicle with asymmetric membrane structure and preparation method thereof
ActiveCN109381705AEnhance specific bindingGood biocompatibilityOrganic active ingredientsGenetic material ingredientsPolyesterCross-link
The invention discloses a reversible cross-linked biodegradable polymer vesicle with an asymmetric membrane structure and a preparation method thereof. Triblock polymers PEG-P(TMC-DTC)-PEI or PEG-P(DLLA-DTC)-PEI is synthesized, and a polymer vesicle with the asymmetric membrane structure is obtained by self-assembly and self-crosslinking of the triblock polymer PEG-P(TMC-DTC)-PEI or PEG-P(DLLA-DTC)-PEI, or targeted RCCPs is obtained by targeted molecule self-assemble, and the inner shell is PEI for complexing and loading of nucleic acids by electrostatic interaction; the membrane is reversiblecross-linked biodegradable well-biocompatible polyester / polycarbonate, side chain dithiolane is similar to human body's natural antioxidant lipoic acid, and the outer shell is PEG-based and can target cancer cells. Studies on vector complex functional siRNA, in-vitro and in-vivo gene silencing effect, in-vivo blood circulation and biodistribution, conditions and toxic and side effects of treatment of mice with orthotopic lung cancer find that the reversible cross-linked biodegradable polymer vesicle is expected to become a simple, stable, multi-functional nano-system platform for efficient, active targeted delivery of siRNA to tumors in situ.
Owner:SUZHOU UNIV
Applications of ZNF367 gene in preparing medicines for treating breast cancer and reagents for realizing diagnosis and prognosis evaluation
ActiveCN106039312AAbility to inhibit metastasisGenetic material ingredientsMicrobiological testing/measurementSurvival analysisDna amplification
The invention discloses applications of a ZNF367 gene in preparing medicines for treating breast cancer and reagents for realizing diagnosis and prognosis evaluation. The in vitro and vivo experimental result of the inventor proves that ZNF367 is highly expressed in the breast cancer tissue, and the survival analysis shows that the expression level of the ZNF367 gene is closely related to the staging and prognosis of breast cancer. Therefore, an inhibitor of the gene can be synthesized or prepared to be taken as the potential targeted medicine for breast cancer; the gene has DNA amplification and expression increase in the breast cancer, therefore, a kit for detecting the DNA variation and expression change of the gene can be prepared for diagnosing the breast cancer; the increase of the gene expression is related to the poor prognosis, and therefore, the kit for detecting the expression level change of the gene also can be used for prognosis evaluation thereof, so that the clinical treatment can be guided.
Owner:SUN YAT SEN UNIV CANCER CENT
Application of siRNA of long non-coding RNA LINC00152 and inhibiting preparation
ActiveCN106511368APrevent invasionAbility to inhibit metastasisOrganic active ingredientsAntineoplastic agentsCancer cellOral Cancers
The invention discloses application of siRNA of long non-coding RNA LINC00152 and an inhibiting preparation. The siRNA sequence of the target LINC00152 is designed and synthesized, the siRNA is transfected into an oral cancer cell line, and thus it is proven that the expression of the target interfering LINC00152 can obviously inhibit the invasion and transfer ability of oral cancer cells. A new potential approach is provided for treatment of oral cancers.
Owner:CENT SOUTH UNIV
ige antibody that inhibits tumor metastasis
ActiveCN105431205BInhibition of the ability to mediate tumor metastasisAbility to inhibit metastasisImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsCancer cellAntiendomysial antibodies
Owner:斯坦福大学董事会
Use of human eddm3a gene and related products
InactiveCN111035762BPrevent proliferationInhibit apoptosisNucleic acid vectorFermentationApoptosisOncology
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Reversible cross-linked biodegradable polymer vesicles with asymmetric membrane structure and its preparation method and application in nucleic acid medicine
ActiveCN106177975BEnhance specific bindingGood biocompatibilityOrganic active ingredientsGenetic material ingredientsCross-linkCancer cell
Owner:SUZHOU UNIV
Application and inhibitory preparation of siRNA of long non-coding RNA LINC00152
ActiveCN106511368BPrevent invasionAbility to inhibit metastasisOrganic active ingredientsGenetic material ingredientsCancer cellNon-coding RNA
The invention discloses application of siRNA of long non-coding RNA LINC00152 and an inhibiting preparation. The siRNA sequence of the target LINC00152 is designed and synthesized, the siRNA is transfected into an oral cancer cell line, and thus it is proven that the expression of the target interfering LINC00152 can obviously inhibit the invasion and transfer ability of oral cancer cells. A new potential approach is provided for treatment of oral cancers.
Owner:CENT SOUTH UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com